More than half of liver cancer patients experience recurrence 5 years after surgery, and the earliest can even recur 2 months after surgery. Patients are most likely to recur 1 to 2 years after surgery, so reducing the recurrence rate after liver cancer surgery is key to improving the overall outcome of liver cancer.
Patients need to be aware that no single drug or treatment can completely stop the recurrence of liver cancer.
For patients with hepatocellular carcinoma with high-risk factors for recurrence, the following treatments can be administered postoperatively to reduce the postoperative recurrence rate and prolong patient survival, such as hepatic artery embolization chemotherapy (TACE), standardized antiviral therapy, hepatoprotective therapy, immunomodulatory therapy with thymidine α1 or α-interferon, sorafenib-targeted therapy, single-agent or combination chemotherapy, and regimen with Sophora granules or Fu Zheng anti-cancer herbs.